CRISPR interference explained

CRISPR interference (CRISPRi) is a genetic perturbation technique that allows for sequence-specific repression of gene expression in prokaryotic and eukaryotic cells.[1] It was first developed by Stanley Qi and colleagues in the laboratories of Wendell Lim, Adam Arkin, Jonathan Weissman, and Jennifer Doudna.[2] Sequence-specific activation of gene expression refers to CRISPR activation (CRISPRa).

Based on the bacterial genetic immune system - CRISPR (clustered regularly interspaced short palindromic repeats) pathway,[3] the technique provides a complementary approach to RNA interference. The difference between CRISPRi and RNAi, though, is that CRISPRi regulates gene expression primarily on the transcriptional level, while RNAi controls genes on the mRNA level.

Background

See also: CRISPR and CRISPR gene editing. Many bacteria and most archaea have an adaptive immune system which incorporates CRISPR RNA (crRNA) and CRISPR-associated (cas) genes.

The CRISPR interference (CRISPRi) technique was first reported by Lei S. Qi and researchers at the University of California at San Francisco in early 2013.[2] The technology uses a catalytically dead Cas9 (usually denoted as dCas9) protein that lacks endonuclease activity to regulate genes in an RNA-guided manner. Targeting specificity is determined by complementary base-pairing of a single guide RNA (sgRNA) to the genomic locus. sgRNA is a chimeric noncoding RNA that can be subdivided into three regions: a 20 nt base-pairing sequence, a 42 nt dCas9-binding hairpin and a 40 nt terminator (bacteria,[4] [5] [6] yeast,[7] fruit flies,[8] zebrafish,[9] mice[10]).

When designing a synthetic sgRNA, only the 20 nt base-pairing sequence is modified. Secondary variables must also be considered: off-target effects (for which a simple BLAST run of the base-pairing sequence is required), maintenance of the dCas9-binding hairpin structure, and ensuring that no restriction sites are present in the modified sgRNA, as this may pose a problem in downstream cloning steps. Due to the simplicity of sgRNA design, this technology is amenable to genome-wide scaling.[11] CRISPRi relies on the generation of catalytically inactive Cas9. This is accomplished by introducing point mutations in the two catalytic residues (D10A and H840A) of the gene encoding Cas9.[12] In doing so, dCas9 is unable to cleave dsDNA but retains the ability to target DNA. Together, sgRNA and dCas9 constitute a minimal system for gene-specific regulation.[2]

Transcriptional regulation

Repression

CRISPRi can sterically repress transcription by blocking either transcriptional initiation or elongation. This is accomplished by designing sgRNA complementary to the promoter or the exonic sequences. The level of transcriptional repression with a target within the coding sequence is strand-specific.Depending on the nature of the CRISPR effector, either the template or non-template strand leads to stronger repression.[13] For dCas9 (based on a Type-2 CRISPR system), repression is stronger when the guide RNA is complementary to the non-template strand. It has been suggested that this is due to the activity of helicase, which unwinds the RNA:DNA heteroduplex ahead of RNA pol II when the sgRNA is complementary to the template strand. Unlike transcription elongation block, silencing is independent of the targeted DNA strand when targeting the transcriptional start site. In prokaryotes, this steric inhibition can repress transcription of the target gene by almost 99.9%; in archaea, more than 90% repression was achieved;[14] in human cells, up to 90% repression was observed.[2] In bacteria, it is possible to saturate the target with a high enough level of dCas9 complex. In this case, the repression strength only depends on the probability that dCas9 is ejected upon collision with the RNA polymerase, which is determined by the guide sequence.[15] Higher temperatures are also associated with higher ejection probability, thus weaker repression.[15] In eukaryotes, CRISPRi can also repress transcription via an effector domain. Fusing a repressor domain to dCas9 allows transcription to be further repressed by inducing heterochromatinization. For example, the well-studied Krüppel associated box (KRAB) domain can be fused to dCas9 to repress transcription of the target gene up to 99% in human cells.[16]

Improvements on the efficiency

Whereas genome-editing by the catalytically active Cas9 nuclease can be accompanied by irreversible off-target genomic alterations, CRISPRi is highly specific with minimal off-target reversible effects for two distinct sgRNA sequences.[16] Nonetheless, several methods have been developed to improve the efficiency of transcriptional modulation. Identification of the transcription start site of a target gene and considering the preferences of sgRNA improves efficiency, as does the presence of accessible chromatin at the target site.[17]

Other methods

Along with other improvements mentioned, factors such as the distance from the transcription start and the local chromatin state may be critical parameters in determining activation/repression efficiency. Optimization of dCas9 and sgRNA expression, stability, nuclear localization, and interaction will likely allow for further improvement of CRISPRi efficiency in mammalian cells.[2]

Applications

Gene knockdown

A significant portion of the genome (both reporter and endogenous genes) in eukaryotes has been shown to be targetable using lentiviral constructs to express dCas9 and sgRNAs, with comparable efficiency to existing techniques such as RNAi and TALE proteins.[16] In tandem or as its own system, CRISPRi could be used to achieve the same applications as in RNAi.

For bacteria, gene knockdown by CRISPRi has been fully implemented and characterized (off-target analysis, leaky repression) for both Gram-negative E. coli and Gram-positive B. subtilis. Not only in bacteria but also in archaea (e.g., M. acetivorans) CRISPRi-Cas9 was successfully utilized to knockdown several genes/operons that related to nitrogen fixation.

Allelic series

Differential gene expression can be achieved by modifying the efficiency of sgRNA base-pairing to the target loci.[11] In theory, modulating this efficiency can be used to create an allelic series for any given gene, in essence creating a collection of hypo- and hypermorphs. These powerful collections can be used to probe any genetic investigation. For hypomorphs, this allows the incremental reduction of gene function as opposed to the binary nature of gene knockouts and the unpredictability of knockdowns. For hypermorphs, this is in contrast to the conventional method of cloning the gene of interest under promoters with variable strength.

Genome loci imaging

Fusing a fluorescent protein to dCas9 allows for imaging of genomic loci in living human cells.[18] Compared to fluorescence in situ hybridization (FISH), the method uniquely allows for dynamic tracking of chromosome loci. This has been used to study chromatin architecture and nuclear organization dynamics in laboratory cell lines including HeLa cells.

Stem cells

Activation of Yamanaka factors by CRISPRa has been used to induce pluripotency in human and mouse cells providing an alternative method to iPS technology.[19] [20] In addition, large-scale activation screens could be used to identify proteins that promote induced pluripotency or, conversely, promote differentiationto a specific cell lineage.[21]

Genetic screening

The ability to upregulate gene expression using dCas9-SunTag with a single sgRNA also opens the door to large-scale genetic screens, such as Perturb-seq, to uncover phenotypes that result from increased or decreased gene expression, which will be especially important for understanding the effects of gene regulation in cancer.[22] Furthermore, CRISPRi systems have been shown to be transferable via horizontal gene transfer mechanisms such as bacterial conjugation and specific repression of reporter genes in recipient cells has been demonstrated. CRISPRi could serve as a tool for genetic screening and potentially bacterial population control.[23]

Advantages and limitations

Advantages

  1. CRISPRi can silence a target gene of interest up to 99.9% repression.[11] The strength of the repression can also be tuned by changing the amount of complementarity between the guide RNA and the target. Contrary to inducible promoters, partial repression by CRISPRi does not add transcriptional noise to the target's expression.[15] Since the repression level is encoded in a DNA sequence, various expression levels can be grown in competition and identified by sequencing.[24]
  2. Since CRISPRi is based on Watson-Crick base-pairing of sgRNA-DNA and an NGG PAM motif, selection of targetable sites within the genome is straightforward and flexible. Carefully defined protocols have been developed.[11]
  3. Multiple sgRNAs can not only be used to control multiple different genes simultaneously (multiplex CRISPRi), but also to enhance the efficiency of regulating the same gene target. A popular strategy to express many sgRNAs simultaneously is to array the sgRNAs in a single construct with multiple promoters or processing elements. For example, Extra-Long sgRNA Arrays (ELSAs) use nonrepetitive parts to allow direct synthesis of 12-sgRNA arrays from a gene synthesis provider, can be directly integrated into the E. coli genome without homologous recombination occurring, and can simultaneously target many genes to achieve complex phenotypes.[25]
  4. While the two systems can be complementary, CRISPRi provides advantages over RNAi. As an exogenous system, CRISPRi does not compete with endogenous machinery such as microRNA expression or function. Furthermore, because CRISPRi acts at the DNA level, one can target transcripts such as noncoding RNAs, microRNAs, antisense transcripts, nuclear-localized RNAs, and polymerase III transcripts. Finally, CRISPRi possesses a much larger targetable sequence space; promoters and, in theory, introns can also be targeted.[16]
  5. In E. coli, construction of a gene knockdown strain is extremely fast and requires only one-step oligo recombineering.[6]

Limitations

  1. The requirement of a protospacer adjacent motif (PAM) sequence limits the number of potential target sequences. Cas9 and its homologs may use different PAM sequences, and therefore could theoretically be utilized to expand the number of potential target sequences.[11]
  2. Sequence specificity to target loci is only 14 nt long (12 nt of sgRNA and 2nt of the PAM), which can recur around 11 times in a human genome.[11] Repression is inversely correlated with the distance of the target site from the transcription start site. Genome-wide computational predictions or selection of Cas9 homologs with a longer PAM may reduce nonspecific targeting.
  3. Endogenous chromatin states and modifications may prevent the sequence-specific binding of the dCas9-sgRNA complex.[11] The level of transcriptional repression in mammalian cells varies between genes. Much work is needed to understand the role of local DNA conformation and chromatin in relation to binding and regulatory efficiency.
  4. CRISPRi can influence genes that are in close proximity to the target gene. This is especially important when targeting genes that either overlap other genes (sense or antisense overlapping) or are driven by a bidirectional promoter.[26]
  5. Sequence-specific toxicity has been reported in eukaryotes, with some sequences in the PAM-proximal region causing a large fitness burden.[27] This phenomenon, called the "bad seed effect", is still unexplained but can be reduced by optimizing the expression level of dCas9.[28]

Notes and References

  1. Jensen TI, Mikkelsen NS, Gao Z, Foßelteder J, Pabst G, Axelgaard E, Laustsen A, König S, Reinisch A, Bak RO . 6 . Targeted regulation of transcription in primary cells using CRISPRa and CRISPRi . Genome Research . 31 . 11 . 2120–2130 . November 2021 . 34407984 . 8559706 . 10.1101/gr.275607.121 .
  2. Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, Lim WA . Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression . Cell . 152 . 5 . 1173–1183 . February 2013 . 23452860 . 3664290 . 10.1016/j.cell.2013.02.022 .
  3. Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, Romero DA, Horvath P . 6 . CRISPR provides acquired resistance against viruses in prokaryotes . Science . 315 . 5819 . 1709–1712 . March 2007 . 17379808 . 10.1126/science.1138140 . free . 3888761 . 2007Sci...315.1709B . 20.500.11794/38902 .
  4. Jiang W, Bikard D, Cox D, Zhang F, Marraffini LA . RNA-guided editing of bacterial genomes using CRISPR-Cas systems . Nature Biotechnology . 31 . 3 . 233–239 . March 2013 . 23360965 . 3748948 . 10.1038/nbt.2508 .
  5. Peters JM, Colavin A, Shi H, Czarny TL, Larson MH, Wong S, Hawkins JS, Lu CH, Koo BM, Marta E, Shiver AL, Whitehead EH, Weissman JS, Brown ED, Qi LS, Huang KC, Gross CA . 6 . A Comprehensive, CRISPR-based Functional Analysis of Essential Genes in Bacteria . Cell . 165 . 6 . 1493–1506 . June 2016 . 27238023 . 4894308 . 10.1016/j.cell.2016.05.003 .
  6. Li XT, Jun Y, Erickstad MJ, Brown SD, Parks A, Court DL, Jun S . tCRISPRi: tunable and reversible, one-step control of gene expression . Scientific Reports . 6 . 39076 . December 2016 . 27996021 . 5171832 . 10.1038/srep39076 . 2016NatSR...639076L .
  7. DiCarlo JE, Norville JE, Mali P, Rios X, Aach J, Church GM . Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems . Nucleic Acids Research . 41 . 7 . 4336–4343 . April 2013 . 23460208 . 3627607 . 10.1093/nar/gkt135 .
  8. Gratz SJ, Cummings AM, Nguyen JN, Hamm DC, Donohue LK, Harrison MM, Wildonger J, O'Connor-Giles KM . 6 . Genome engineering of Drosophila with the CRISPR RNA-guided Cas9 nuclease . Genetics . 194 . 4 . 1029–1035 . August 2013 . 23709638 . 3730909 . 10.1534/genetics.113.152710 .
  9. Hwang WY, Fu Y, Reyon D, Maeder ML, Tsai SQ, Sander JD, Peterson RT, Yeh JR, Joung JK . 6 . Efficient genome editing in zebrafish using a CRISPR-Cas system . Nature Biotechnology . 31 . 3 . 227–229 . March 2013 . 23360964 . 3686313 . 10.1038/nbt.2501 .
  10. Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, Zhang F, Jaenisch R . One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering . Cell . 153 . 4 . 910–918 . May 2013 . 23643243 . 3969854 . 10.1016/j.cell.2013.04.025 .
  11. Larson MH, Gilbert LA, Wang X, Lim WA, Weissman JS, Qi LS . CRISPR interference (CRISPRi) for sequence-specific control of gene expression . Nature Protocols . 8 . 11 . 2180–2196 . November 2013 . 24136345 . 3922765 . 10.1038/nprot.2013.132 .
  12. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E . A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity . Science . 337 . 6096 . 816–821 . August 2012 . 22745249 . 6286148 . 10.1126/science.1225829 . 2012Sci...337..816J .
  13. Vigouroux A, Bikard D . CRISPR Tools To Control Gene Expression in Bacteria . Microbiology and Molecular Biology Reviews . 84 . 2 . May 2020 . 32238445 . 7117552 . 10.1128/MMBR.00077-19 .
  14. Dhamad AE, Lessner DJ . A CRISPRi-dCas9 System for Archaea and Its Use To Examine Gene Function during Nitrogen Fixation by Methanosarcina acetivorans . Applied and Environmental Microbiology . 86 . 21 . e01402–20 . October 2020 . 32826220 . 7580536 . 10.1128/AEM.01402-20 . 2020ApEnM..86E1402D . Atomi H .
  15. Vigouroux A, Oldewurtel E, Cui L, Bikard D, van Teeffelen S . Tuning dCas9's ability to block transcription enables robust, noiseless knockdown of bacterial genes . Molecular Systems Biology . 14 . 3 . e7899 . March 2018 . 29519933 . 5842579 . 10.15252/msb.20177899 .
  16. Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE, Stern-Ginossar N, Brandman O, Whitehead EH, Doudna JA, Lim WA, Weissman JS, Qi LS . 6 . CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes . Cell . 154 . 2 . 442–451 . July 2013 . 23849981 . 3770145 . 10.1016/j.cell.2013.06.044 .
  17. Radzisheuskaya A, Shlyueva D, Müller I, Helin K . Optimizing sgRNA position markedly improves the efficiency of CRISPR/dCas9-mediated transcriptional repression . Nucleic Acids Research . 44 . 18 . e141 . October 2016 . 27353328 . 5062975 . 10.1093/nar/gkw583 .
  18. Chen B, Gilbert LA, Cimini BA, Schnitzbauer J, Zhang W, Li GW, Park J, Blackburn EH, Weissman JS, Qi LS, Huang B . 6 . Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system . Cell . 155 . 7 . 1479–1491 . December 2013 . 24360272 . 3918502 . 10.1016/j.cell.2013.12.001 .
  19. Kearns NA, Genga RM, Enuameh MS, Garber M, Wolfe SA, Maehr R . Cas9 effector-mediated regulation of transcription and differentiation in human pluripotent stem cells . Development . 141 . 1 . 219–223 . January 2014 . 24346702 . 3865759 . 10.1242/dev.103341 .
  20. Hu J, Lei Y, Wong WK, Liu S, Lee KC, He X, You W, Zhou R, Guo JT, Chen X, Peng X, Sun H, Huang H, Zhao H, Feng B . 6 . Direct activation of human and mouse Oct4 genes using engineered TALE and Cas9 transcription factors . Nucleic Acids Research . 42 . 7 . 4375–4390 . April 2014 . 24500196 . 3985678 . 10.1093/nar/gku109 .
  21. Takahashi K, Yamanaka S . Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors . Cell . 126 . 4 . 663–676 . August 2006 . 16904174 . 10.1016/j.cell.2006.07.024 . free . Shinya Yamanaka . 1565219 . 2433/159777 .
  22. Tanenbaum ME, Gilbert LA, Qi LS, Weissman JS, Vale RD . A protein-tagging system for signal amplification in gene expression and fluorescence imaging . Cell . 159 . 3 . 635–646 . October 2014 . 25307933 . 4252608 . 10.1016/j.cell.2014.09.039 .
  23. Ji W, Lee D, Wong E, Dadlani P, Dinh D, Huang V, Kearns K, Teng S, Chen S, Haliburton J, Heimberg G, Heineike B, Ramasubramanian A, Stevens T, Helmke KJ, Zepeda V, Qi LS, Lim WA . 6 . Specific gene repression by CRISPRi system transferred through bacterial conjugation . ACS Synthetic Biology . 3 . 12 . 929–931 . December 2014 . 25409531 . 4277763 . 10.1021/sb500036q .
  24. 10.1101/805333. 805333. Hawkins JS, Silvis MR, Koo BM, Peters JM, Jost M, Hearne CC, Weissman JS, Todor H, Gross CA . 6 . Modulated efficacy CRISPRi reveals evolutionary conservation of essential gene expression-fitness relationships in bacteria. bioRxiv. 2020-01-16. 2019-10-15. 208583386. free.
  25. Reis AC, Halper SM, Vezeau GE, Cetnar DP, Hossain A, Clauer PR, Salis HM . Simultaneous repression of multiple bacterial genes using nonrepetitive extra-long sgRNA arrays . Nature Biotechnology . 37 . 11 . 1294–1301 . November 2019 . 31591552 . 10.1038/s41587-019-0286-9 . 1569832 . 203852115 .
  26. Goyal A, Myacheva K, Groß M, Klingenberg M, Duran Arqué B, Diederichs S . Challenges of CRISPR/Cas9 applications for long non-coding RNA genes . Nucleic Acids Research . 45 . 3 . e12 . February 2017 . 28180319 . 5388423 . 10.1093/nar/gkw883 .
  27. Cui L, Vigouroux A, Rousset F, Varet H, Khanna V, Bikard D . A CRISPRi screen in E. coli reveals sequence-specific toxicity of dCas9 . Nature Communications . 9 . 1 . 1912 . May 2018 . 29765036 . 5954155 . 10.1038/s41467-018-04209-5 . 2018NatCo...9.1912C .
  28. Depardieu F, Bikard D . Gene silencing with CRISPRi in bacteria and optimization of dCas9 expression levels . Methods . 172 . 61–75 . February 2020 . 31377338 . 10.1016/j.ymeth.2019.07.024 . Methods for characterizing, applying, and teaching CRISPR-Cas systems . 199436713 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "CRISPR interference".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.